EBV vac: New Safe Vaccine for Prevention of Epstein-Barr Virus Infections
Professor Ritter and his co-workers from the Division of Virology, University Hospital of the RWTH Aachen, created a new recombinant Epstein-Barr Virus (EBV)
which has lost the ability to enter the state of latent persistency after infecting host cells. The mutant virus only causes a self-limited infection and is unable to immortalize B-lymphocytes following Infection. Having lost the oncogenic potential of wild type EBV it fulfils the prerequisite for a live vaccine. The inventors generated a mutant virus allowing expression of lytic genes, but preventing the expression of EBV encoded genes essential for the establishment of viral latency. Mutant virus infected B-lymphocytes died after the productive phase.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Going Steady—Study Reveals North Atlantic’s Gulf Stream Remains Robust
A study by the University of Bern and the Woods Hole Oceanographic Institution in the USA concludes that the ocean circulation in the North Atlantic, which includes the Gulf Stream,…
Single-Celled Heroes: Foraminifera’s Power to Combat Ocean Phosphate Pollution
So-called foraminifera are found in all the world’s oceans. Now an international study led by the University of Hamburg has shown that the microorganisms, most of which bear shells, absorb…
Humans vs Machines—Who’s Better at Recognizing Speech?
Are humans or machines better at recognizing speech? A new study shows that in noisy conditions, current automatic speech recognition (ASR) systems achieve remarkable accuracy and sometimes even surpass human…